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ABSTRACT 
Splenic marginal zone B (MZB) cells, positioned at the interface between the 
circulating blood and lymphoid tissue, detect and respond to blood-borne antigens. 
Here, we show that MZB cells in mice activate a homeostatic program in response to 
a high cholesterol diet (HCD), and regulate both T follicular helper (Tfh) cell 
differentiation and accumulation. HCD feeding upregulated MZB cell surface 
expression of the immunoregulatory ligand PDL1 in an ATF3-dependent manner 
and increased the interaction between MZB cells and (pre-)Tfh cells, leading to 
PDL1-mediated suppression of Tfh cell motility, alteration of Tfh cell 
differentiation, reduced Tfh abundance and suppression of the pro-atherogenic Tfh 
response. Our findings reveal a previously unsuspected role for MZB cells in 
controlling the Tfh–germinal center response to a cholesterol-rich diet, and uncover 
a PDL1-dependent mechanism by which MZB cells use their innate immune 
properties to limit an exaggerated adaptive immune response.  
  
   
 4 
 
The development of atherosclerotic arterial lesions in response to elevated circulating 
lipid levels is characterized by an inflammatory activation of the vascular wall, and is 
associated with the induction of innate and adaptive immune responses directed at least in 
part towards (modified) lipoproteins 1,2. More specifically, B lymphocyte-dependent 
immune responses play prominent roles in atherosclerosis. B1-derived natural IgM 
antibodies have consistently been shown to be athero-protective (reviewed in 3,4). In 
contrast, B2 cell responses promote atherogenesis 5-8 through their support of pro-
atherogenic T cells 5. So-called regulatory B cells originate from the B2 cell compartment 
and are involved in the control of exaggerated adaptive immune responses 9-11. However, 
their developmental pathway is not well understood and their contribution to 
atherosclerosis is still uncertain 12,13. Importantly, there are 2 major B2 cell subsets, 
follicular (FOB) and the marginal zone B (MZB) cells, with distinct developmental 
pathways and functional properties 14. While the contribution of adaptive FOB cells to the 
development of atherosclerosis can be inferred from their roles in the support of pro-
atherogenic T follicular helper (Tfh) cells and germinal center (GC) responses 15, the 
potential contribution of innate-like MZB cells to the regulation of the immune response 
to high cholesterol diet (HCD) cannot be easily predicted and remains almost unexplored, 
apart from the reported ability of this B2 cell subset to mount T-independent responses to 
(modified) lipoproteins (e.g., oxidized phosphatidylcholine epitopes) 16. 
 
RESULTS 
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MZB cells limit the development of atherosclerosis through inhibition of the Tfh 
response 
To address the role of MZB cells in atherosclerosis, we generated mice with B cell 
lineage-specific (Cd79aCre/+) conditional deletion of the gene Rbpjk (Rbpjkflox/flox), which 
encodes the effector transcription factor downstream of the Notch2 receptor and which is 
known to be required for MZB cell development 17-19. We then reconstituted lethally-
irradiated low-density lipoprotein receptor deficient (Ldlr−/−) mice with bone marrow from 
either Cd79aCre/+;Rbpjkflox/flox or Cd79a+/+;Rbpjkflox/flox control mice. After recovery, these 
mice were put on a HCD for 8 weeks or 16 weeks. In Cd79aCre/+;Rbpjkflox/flox mice, 
disruption of Notch signaling in B cells induced a selective depletion of splenic MZB 
cells (Fig. 1a and Supplementary Fig. 1a) and markedly accelerated the development of 
both early (Fig. 1b and Supplementary Fig. 1b) and advanced atherosclerotic lesions (Fig. 
1c) as compared to control mice, despite not having effects on plasma lipid parameters 
(Supplementary Fig. 1c-f). Analysis of plaque composition showed sustained 
accumulation of macrophages and CD3+ T cells in the lesions of MZB cell-deficient mice 
(Supplementary Fig. 1g-j). We detected only subtle changes in antibody responses against 
modified LDL (Supplementary Fig. 1k-n), which could not account for the marked 
acceleration of atherosclerosis in MZB cell-deficient animals. The abundance of 
neutrophils (Supplementary Fig. 2a) and monocytes/macrophages (Supplementary Fig. 
2b, c) in the spleen were similar between  MZB-cell deficient and control mice. We 
therefore assessed the effect of MZB cell deficiency on peripheral T cell activation status, 
and found that MZB cell-deficient mice had increased percentages of splenic CD4+ T 
effector memory CD44hiCD62L− cells (Fig. 2a) and Th2 cells (Supplementary Fig. 2d) 
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with a trend towards an increased percentage of Th1 but no change in the percentages of 
Th17 and regulatory T cells (Supplementary Fig. 2e-g), as compared to control mice. 
Intriguingly, we also found a substantial accumulation of Tfh cells (CD4+CXCR5hiPD1hi) 
in the spleens of MZB deficient mice (Fig. 2b), whereas the percentage of Tfh cells was 
not significantly higher in lymph nodes of MZB as compared to control mice (1.78±0.4% 
of CD4+ T cells, n=7, versus 0.93±0.18%, n=8, respectively; p=0.061). Moreover, 
irradiated Ldlr−/− mice that had been maintained on a chow diet for 8 weeks did not display 
an increased percentage of splenic Tfh cells (0.54±0.057%) in comparison to Ldlr−/− mice 
fed a HCD, indicating that HCD is required for induction of a Tfh response. Notably, 
MZB cell-deficiency did not accelerate the development of atherosclerosis in the absence 
of CD4+ T cells (Fig. 2c). Furthermore, selective Tfh cell depletion using an anti-ICOSL 
neutralizing antibody (Supplementary Fig. 2h-k) abrogated the acceleration of 
atherosclerosis in MZB cell-deficient mice (Fig. 2d), highlighting the role of the Tfh cell 
response in the pro-atherogenic phenotype caused by MZB cell deficiency. Ldlr−/− mice 
reconstituted with Cd79aCre/+ bone marrow did not show an increase in Tfh cell numbers 
or atherosclerotic lesion size after 8 weeks on a HCD, as compared to mice reconstituted 
with Cd79a+/+ bone marrow (data not shown), indicating that deletion of one Cd79a 
allele does not alter the Tfh response or the development of atherosclerosis.  
 
A high cholesterol diet activates a homeostatic and anti-inflammatory program in 
MZB cells 
As modulation of Tfh responses by MZB cells has not been described previously, we 
used an unbiased approach to gain mechanistic insight. After sorting MZB cells from 
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Ldlr−/− mice after 8 weeks on chow diet or HCD and performing RNA sequencing (RNA-
seq), we found that 71 genes were significantly upregulated and 21 genes were 
significantly downregulated (p < 0.0004; q < 0.01 for all up- and down-regulated genes) 
in MZB cells after HCD (Fig. 3a-b). Among the highly regulated genes were genes 
involved in B cell receptor (BCR) signaling, B cell activation, cell cycle regulation and 
trafficking (e.g., Nr4a1, Egr1, Fos, Junb, Klf2, Klf4, Rap1b, Cd69), communication 
between the innate and adaptive immune systems (e.g., Ccr7, Cd83, Cd274), lipid 
metabolism (e.g., Abcg1, Atf3, Nr4a1) and regulation of immune and inflammatory 
responses (e.g., Fos/Fosb, Jun/Junb, Crem, Atf3, Tnfaip3, Nfkbid, Dusp1, Dusp4, Il10). 
Intriguingly, we also found a significant induction of pathways that are critical for the 
maintenance of metabolic and immune homeostasis, notably the NF-κB (Tnfaip3, Nfkibd, 
Atf3, Nr4a1, Dusp1/4) and AP1 (Fos, Jun, Atf3, Crem, Dusp1/4) pathways. 
 
ATF3 expression in MZB cells control Tfh cell accumulation in response to HCD 
and is required for the atheroprotective effect of MZB cells 
The gene encoding ATF3, a member of the CREB/ATF family of transcription factors, 
was the most highly upregulated transcription factor gene in MZB cells after HCD (Fig. 
3a) and bioinformatic analysis indicated that ATF3 could potentially link several 
pathways downstream of innate and adaptive immune receptors (Fig. 3c-d). ATF3 
regulation of metabolic and immune pathways is well documented in cell types other than 
B cells, most notably in macrophages. In response to lipid loading, ATF3 suppresses the 
transcription of Ch25h, which encodes the enzyme cholesterol 25-hydroxylase that 
converts cholesterol into 25-hydroxycholesterol, thereby limiting foam cell formation 20; 
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in response to stimulation with HDL-cholesterol or downstream of TLR4 activation 
(which can be triggered by macrophage treatment with oxLDL or free fatty acids), ATF3 
interacts with NF-κB1 and AP1 to induce a major negative feedback loop and shut down 
pro-inflammatory responses21,22. These regulatory functions of ATF3 are consistent with 
our finding that Atf3 upregulation in MZB cells after HCD was accompanied by negative 
regulation of TLR signaling (analysis with Ingenuity software, p=1.38x10-3) (Fig 3c). 
Moreover, we found that the NF-E2 related factor 2 (NRF2)-mediated oxidative stress 
response was the most significantly activated Ingenuity canonical pathway in MZB cells 
after HCD (p=3.02x10-4) (Fig 3c), consistent with a previous report that Atf3 is strongly 
induced by NRF2 in response to reactive oxygen species (ref. 23). Thus, our data suggest 
a potentially dominant role for ATF3 in orchestrating the regulatory program induced in 
MZB cells after HCD.  
 
The function of ATF3 in B lymphocytes is unknown. Since HCD increases the level of 
circulating endotoxin in mice (Supplementary Fig. 3a) and humans (reviewed in 24), we 
analyzed the response of WT and Atf3-/- MZB cells to LPS. Il6 is a prototypical TLR4-
induced inflammatory gene that is directly repressed by ATF3 in macrophages 21,22. We 
found that ATF3 similarly limits Il6 expression in LPS-treated MZB cells (Fig. 4a). We 
also found that ATF3 deficiency in MZB cells prevented LPS-induced upregulation of 
both gene and protein expression of PDL1 (encoded by Cd274) (Fig. 4b, c), a ligand for 
PD1 (encoded by Pdcd1) and a potential regulator of the Tfh response 25.  
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To examine the impact of ATF3 deficiency in MZB cells on the immune response to 
HCD in vivo, we reconstituted lethally-irradiated Ldlr−/− mice with bone marrow from 
Cd79aCre/+;Rbpjkflox/flox mice (the ‘no MZB’ group) and compared them to Ldlr−/− mice 
reconstituted with mixed bone marrow containing 80% Cd79aCre/+;Rbpjkflox/flox bone 
marrow + either 20% wild-type bone marrow  (the ‘WT MZB’ group) or 20% Atf3−/− bone 
marrow (the ‘Atf3-/- MZB’ group) (see Methods). As expected, MZB cells were 
completely absent in the no MZB group and were fully reconstituted in the WT MZB and 
Atf3-/- MZB groups (Supplementary Fig. 3b). Consistent with the in vitro data, PDL1 
expression was markedly reduced on reconstituted Atf3-/- MZB cells compared to WT 
MZB cells (Fig. 4d-e). Reconstitution of MZB-deficient mice with WT MZB cells 
significantly reduced the accumulation of Tfh and GC B cells in the spleen  (Fig. 4f-g) 
and fully rescued the accelerated atherosclerosis phenotype caused by MZB cell 
deficiency (Fig. 4h-i), despite not having effects on plasma cholesterol levels 
(Supplementary Fig. 3c) or plaque composition (Supplementary Fig. 3d-e). However, 
reconstitution with Atf3-deficient MZB cells was unable to limit the pro-atherogenic 
Tfh/GC response of MZB cell deficiency (Fig. 4f-i), providing direct evidence for the 
critical regulatory and homeostatic roles of ATF3 expression in MZB cells in response to 
HCD. 
  
MZB cells limit Tfh cell motility through upregulation of PDL1 
We next examined whether a direct interaction between MZB and T cells is required to 
limit the Tfh response. We hypothesized that MZB cells may need to migrate to the 
splenic follicle in order to interfere with Tfh cells. MZB cells continuously shuttle 
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between the marginal zone and the follicle, and CXCR5 expression on MZB cells is 
required to induce their translocation into the follicle upon downregulation of S1PR1 26. 
We therefore reconstituted Ldlr−/− MZB-deficient mice with Cxcr5−/− or WT MZB cells 
(see Methods). MZB cell reconstitution was similar between Cxcr5−/− and WT MZB 
groups (7.42±1.68% and 6.81±0.64%, respectively, n=8 in each group). In contrast to our 
expectation, Cxcr5 deletion in MZB cells did not impair their ability to reduce Tfh cell 
accumulation (3.52% and 3.54% in the WT and Cxcr5-/- MZB cells groups, respectively 
n=8 in each group), suggesting that MZB cell shuttling to the follicle is not required for 
the inhibitory role of MZB cells on Tfh cell accumulation.  
 
We therefore hypothesized that MZB cells may exert their control on the Tfh response by 
interacting with (pre)-Tfh cells in the T cell zone or at the T-B border of the spleen, prior 
to Tfh translocation into the follicle. B cell movement into the T cell zone and to the T-B 
border requires the coordinated actions of the CCR7 and EBI2 receptors (reviewed in 
27,28). Cell-sorted MZB cells, but not FOB cells, recovered from Ldlr−/− mice showed 
increased expression of Ccr7 and Ebi2 in response to HCD as compared to chow diet 
(Supplementary Fig. 4a-b), suggesting that HCD might promote MZB cell movement into 
the T cell zone and the T-B border 27,28. Consistent with this hypothesis, we found that 
HCD led to increased accumulation of IgMhi MZB-like cells at the boundary of the T cell 
zone, where IgMhi B cells established close cell-cell contacts with CXCR5+CD4+ T cells 
(Supplementary Fig. 4c-d). 
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We next sought to test whether physical interaction of MZB and Tfh cells is required for 
downregulation of the Tfh response. In studying the interaction between MZB and Tfh 
cells, we focused on the PDL1/PD1 axis for several reasons. MZB cells express the 
highest level of PDL1 of the B cell subsets tested (Supplementary Fig. 5a), and we noted 
in the RNA-seq data that HCD led to upregulation of Cd274 expression in MZB cells, a 
finding that was confirmed by qPCR and cell surface expression data (Fig. 5a). Notably, 
in FOB cells, HCD led to upregulation of Icosl but not Cd274 (Fig. 5b), which is of 
interest in the context of previous findings showing that ICOS and PD1 signaling have 
contrasting roles in Tfh cells; the former is required for instructing Tfh cell differentiation 
(reviewed in 29), whereas the latter limits the number of Tfh cells and regulates the 
survival of GC B cells 25.  
 
When we cultured sorted and labeled Tfh cells in vitro with cell-sorted MZB or FOB 
cells (all from immunized wild type mice, see Methods), we found that co-culture with 
MZB cells resulted in significantly lower levels of Tfh cell velocity and motility, as 
compared to co-culture with FOB cells (Fig. 5c-d). Moreover, contact time and the 
number of Tfh cells interacting with B cells were significantly higher when Tfh cells 
were co-cultured with MZB as compared to FOB cells (Fig. 5e). These differences were 
abrogated when a blocking anti-PDL1 antibody was added to the co-culture (Fig. 5c-e), 
indicating that the inhibitory effect of MZB on Tfh relies on PDL1. Our results are 
consistent with previous work that reported PD1-dependent immune exhaustion through 
induction of antiviral T cell motility paralysis 30. In another experiment, we found that 
incubation of Tfh cells with MZB cells from Ldlr−/− mice fed HCD significantly decreased 
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Tfh cell velocity and increased contact time, in comparison to incubation with MZB cells 
from Ldlr−/− mice fed chow diet (Supplementary Fig. 5b, c), consistent with the 
upregulation of PDL1 expression in MZB cells after HCD.  
 
BCR signaling promotes PDL1 expression in MZB cells 
We were interested by the high expression of PDL1 on MZB as compared to FOB cells. 
Those B cell subsets may differ in BCR signaling strength, and the BCR signaling 
pathway was modulated in MZB cells after HCD. Indeed, we found that direct 
engagement of IgM on purified MZB cells increased both gene and protein expression of 
PDL1, and these effects were dependent on Btk activation (Supplementary Fig. 6a-d). We 
next examined human circulating MZB-like cells 31,32 and found that they expressed 
higher levels of PDL1 as compared to circulating naïve B cells  (Supplementary Fig. 6e). 
Stimulation of BCR signaling further induced PDL1 expression in these human MZB-like 
cells (Supplementary Fig. 6f, g). We also noted that human splenic MZB cells 31,32 
expressed much higher levels of PDL1 as compared to naïve splenic B cells 
(Supplementary Fig. 6h). We conclude both murine and human MZB cells show 
comparatively high levels of PDL1 expression compared to other B cell populations, and 
that PDL1 expression in MZB cells is regulated by BCR signaling  
 
MZB cells control the pro-atherogenic Tfh-GC response through upregulation of 
PDL1 
To address the direct role of MZB cell-restricted PDL1 expression in modulation of the 
Tfh-GC response in vivo, we reconstituted MZB-deficient Ldlr−/− mice with WT or 
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Cd274−/− MZB cells (see Methods). Similar levels of MZB cell reconstitution was 
achieved in the 2 groups of mice (Supplementary Fig. 7a). As expected, PDL1 expression 
was almost abrogated on reconstituted MZB cells in the Cd274-/- MZB group as 
compared to the WT MZB group (Supplementary Fig. 7b). Strikingly, reconstitution of 
Ldlr-/- with Cd274-deficient MZB cells was unable to limit the Tfh-GC response to HCD 
(Fig. 5f-g), such that the Cd274-/- MZB group had more severe atherosclerosis as 
compared to the WT group [(Fig. 5h and Supplementary Fig. 7c-g), providing evidence 
that PDL1 expression in MZB cells limits the pro-atherogenic Tfh response.  
 
MZB cell deficiency alters the Tfh cell program 
We were surprised by the absence of a clear increase in antibody levels (Supplementary 
Fig. 1k-n) despite the increased numbers of Tfh cells in MZB-deficient mice after HCD. 
This finding is reminiscent of the effects of PD1 deficiency in T cells 25, which led to an 
increase in Tfh cell numbers but an impairment of Tfh quality; in particular, PD1-
deficient Tfh cells had reduced production of  IL-21, a cytokine that is required for 
optimal antibody responses 33. This previous work fits with our identification of a major 
role of MZB-restricted PDL1 expression in the regulation of the Tfh response, through 
interaction of PDL1 on MZB cells with PD1 on Tfh cells.  
 
To better characterize the Tfh cells that develop in MZB-deficient mice after HCD, we 
performed RNA-seq on cell-sorted spleen Tfh cells after 8 weeks on HCD in lethally-
irradiated Ldlr−/− mice reconstituted with bone marrow from Cd79aCre/+;Rbpjkflox/flox mice 
(the ‘no MZB’ group) or from Cd79a+/+;Rbpjkflox/flox mice (the ‘WT MZB’ group). We 
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focused on the expression of a subset of genes associated with, or directly involved in the 
determination of Tfh cell identity. We did not find significant differences in the 
expression of Bcl6, Cxcr5 and Pdcd1 between the two groups, although we found a 
tendency towards reduced Bcl6 (p=0.07) and Cxcr5 (p=0.14) expression in the no MZB 
group compared to the WT MZB group. Notably, we found a significant reduction of Il21 
expression in the no MZB group (Fig. 6a, b), supporting the hypothesis that the quality of 
Tfh cells from MZB-deficient mice is impaired, and providing a plausible explanation for 
the absence of an overt increase in antibody response, despite increased Tfh cell numbers, 
in MZB-deficient animals. Further analysis of the RNA-seq data revealed differences in 
the expression of major transcription factors and pathways involved in the control of Tfh 
cell differentiation between the two groups of mice (Fig. 6): genes that limit the 
differentiation of Tfh cells were upregulated in the no MZB group, whereas pathways 
that promote Tfh cell development were downregulated. For example, recent studies have 
identified an important role for KLF2 in limiting the differentiation of Tfh cells through 
induction of S1pr1 34, and expression of both Klf2 and S1pr1 were significantly 
upregulated (at least 2-fold) in the no MZB group (Fig. 6a,b). In contrast to S1pr1, we 
found that expression of S1pr2, which supports Tfh cell differentiation and promotes Tfh 
cell retention in GCs 35, was substantially reduced in the no MZB group (Fig. 6a, d). 
Decreased expression of S1PR2 in Tfh cells is associated with decreased expression of 
Il21 but higher expression of Ccr7, Ccr6, S1pr1 and Sell 35, a pattern that we also 
observed in the no MZB group (Fig. 6a). Furthermore, expression of Icos, which 
downregulates Klf2 36, and Maf, which promotes the expression of several Tfh cell-
related genes, including Il21 and Cxcr5 37, were both significantly downregulated in the 
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no MZB group (Fig. 6a, b, d). Finally, expression of Ascl2, which interacts with 
BATF/IRF4 to orchestrate the Tfh program through induction of CXCR5 and suppression 
of CCR7 expression and IL-2 signaling 38, was significantly downregulated in the no 
MZB group, along with downregulated expression of Irf4 and upregulated expression of 
Ccr7 and Il2ra (Fig. 6). Differential regulation of Icos and Il2ra may control the 
bifurcation between effector Th and Tfh programs 39, a concept which is in agreement 
with the over-representation of those pathways in the Ingenuity canonical pathway 
analysis of the RNA-seq data (Fig. 6c).   
 
DISCUSSION 
Only a few previous studies have addressed the role of MZB cells in a 
hypercholesterolemic context 16,40. MZB cell abundance increases in the spleens of 
hypercholesterolemic Apoe−/− mice compared to wild type animals, due in part to 
decreased IFNγ release by iNKT cells 40. MZB cells also ingest modified LDL and mount 
extra-follicular antibody responses against oxidation-specific epitopes 16. However, the 
contribution of MZB cells to atherosclerosis was unexplored. Our results identify a 
critical role for MZB cells in the establishment of an optimal Tfh program in response to 
HCD, limiting exaggerated adaptive immune responses and substantially halting the 
development and progression of atherosclerosis. 
 
These findings raise several important questions that require further exploration. For 
example, what signals activate MZB cells after HCD? Our RNA-seq data point to the 
involvement of the TLR and BCR signaling pathways. One potential factor leading to 
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MZB cell activation after HCD is diet-induced translocation of endotoxin from the gut to 
the circulation, but there are many other possibilities, including activation by oxidation-
specific epitopes from modified self proteins and lipids, and the direct or indirect impact 
of the gut microbiota. In this regard, a recent study reported induction of regulatory B 
cells by gut microbiota-driven IL-1β and IL-6 41. Thus, a better understanding of the 
major determinants of MZB cell activation after HCD is needed. 
 
In view of our findings that, in HCD-fed mice, MZB cells leave the marginal zone and 
interact with (pre)Tfh cells, it will be important to study the signals that instruct the MZB 
cells to leave the marginal zone and guide them to Tfh cells. In this regard, we did not 
observe downregulation of S1pr1 expression or increased expression of Cxcr5, the major 
receptors that control the shuttling of MZB cells between the marginal zone and the 
follicle 26. Moreover, Cxcr5 deletion in MZB cells did not alter their ability to regulate 
the Tfh cell response. Our data point to other possible mechanisms: for example, as 
expression of Cd69, which suppresses the function of S1PR1 42, was highly upregulated 
in MZB cells after HCD, it may be responsible for MZB cell egress from the marginal 
zone. On the other hand, MZB cells after HCD also upregulate CCR7 and EBI2, the latter 
of which is a receptor for oxysterols 43,44; CCR7 and EBI2 may facilitate MZB cell 
movement to the T cell zone and the T-B border, respectively. 
  
Our findings indicate that PDL1 expression in MZB cells regulates Tfh cell motility 
through induction of PD1 signaling in (pre)-Tfh cells. Previous work has unraveled a 
critical role for ICOSL expression on FOB cells in ICOS-driven T cell motility at the T-B 
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border, whereby FOB cells promote the recruitment of Tfh cells into the follicle 45. In this 
regard, the differential upregulation of Cd274 and Icosl in MZB compared with FOB 
cells (Fig. 5a-b) suggests that FOB and MZB cells have contrasting roles in response to 
HCD: FOB cells promote Tfh cell development whereas MZB cells shut down any 
exaggerated activation of the Tfh response. 
 
Our results agree with previous studies that reported increased pro-atherogenic T cell 
responses in mice after combined deficiency of PDL1 and PDL2 46 or after impairment of 
PD1 47. However, the mechanisms proposed in these previous studies differed and were 
attributed mainly to macrophage or dendritic cell-dependent alteration of T cell 
activation. Our results substantially extend these previous findings by identifying PDL1 
expression in MZB cells as a major regulator of the pro-atherogenic Tfh response. Our 
results are also in agreement with a recent study that reported regulation of Tfh cells by B 
cells expressing high levels of PDL1 in a setting of experimental autoimmune 
encephalomyelitis 48. However, the specific role of MZB cells in the regulation of 
immune responses in this context was not reported.  
 
Our work identifies an important role for MZB cells in the regulation of the Tfh cell 
program, but additional work will be required to fully address the mechanisms through 
which MZB cells control Tfh differentiation. For example, expression of the transcription 
factor BLIMP1 was downregulated in Tfh cells of MZB deficient mice. As this 
transcription factor is an antagonist of BCL6 and a major inhibitor of Tfh differentiation 
49, it will be interesting to study the mechanisms underlying its downregulation. Although 
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PD1 signaling in Tfh cells has been reported to regulate follicular regulatory T cells in 
blood and lymph nodes 50, we did not find an effect of MZB deficiency on Foxp3 
expression in Tfh cells (data not shown), suggesting little or no effect of MZB deficiency 
on regulatory Tfh cells. However, we did detect reduced expression of Ctla4 in Tfh cells 
of MZB deficient animals (Figure 6a), suggesting increased susceptibility of Tfh cells to 
activation, consistent with the increased number of effector memory T cells in the 
absence of MZB cells (Figure 2a). 
 
Our work did not address the mechanisms through which Tfh cells promote atherogenesis 
when released from the negative regulatory influence of MZB cells. The changes caused 
by MZB cell deficiency in the levels of circulating antibodies directed against oxidation 
epitopes were variable, and did not correlate with the acceleration of atherosclerosis. 
However, a more detailed assessment of the humoral response in MZB cell-deficient 
mice should be carried out before reaching any definite conclusions about the 
contribution of the GC response to the atherosclerotic phenotype of these mice.  
 
In conclusion, this work reveals a new role for MZB cells in maintaining immune 
homeostasis in response to a HCD through activation of a regulatory program affecting 
both the quantity and quality of Tfh cells. MZB cells appear to be required for optimal 
Tfh cell differentiation while restraining the Tfh response. Absence of MZB cells leads to 
excessive accumulation of sub-optimally differentiated Tfh cells and increased levels of 
Th and T effector memory cells. These results may have important implications to our 
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understanding of the impact of environmental influences, such as variations in diet 
composition, on the initiation and/or progression of immune-mediated diseases.  
 
METHODS 
Please see a full description of Materials and Methods in the online version of the paper 
in Supplementary data. 
Accesion Codes 
MZB cells and Tfh cells RNAseq data at GSE71699. 
Data Availability Statement 
The data of the findings of this study are available from the corresponding author upon 
reasonable request.  
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FIGURE LEGENDS 
Figure 1. Marginal zone B cells limit the development of atherosclerosis. Ldlr-/- mice 
were transplanted with donor bone marrow cells from Cd79aCre/+;Rbpjkflox/flox or 
Cd79a+/;/Rbpjkflox/flox mice after consumption of a high cholesterol diet for 8 (a-b) or 16 
(c) weeks. (a) Representative flow cytometry plots and total numbers of the indicated 
splenic B cell subsets by flow cytometry (n=9 mice per group). T2-MZP refers to 
transitional T2 and marginal zone progenitor B cells; T1 refers to transitional T1 B cells 
(see Methods). Data are presented as box-and-whisker plots. (b, c) Representative images 
of Masson trichrome staining and quantification of atherosclerotic plaque area in aortic 
roots (each symbol represents an individual mouse; horizontal bars denote mean ± 
s.e.m.). Original magnification, x10. Scale bars, 500 µm. For (a-c), two-tailed unpaired 
Student t-test or 2 way Anova * p<0.05; **p<0.01 and ***p<0.001. 
 
Figure 2. Marginal zone B cells limit the development of atherosclerosis through 
inhibition of the Tfh response. Ldlr-/- mice were transplanted with donor bone marrow 
cells from Cd79aCre/+;Rbpjkflox/flox or Cd79a+/;/Rbpjkflox/flox mice after the consumption of 
a high cholesterol (a-d) diet for 8 weeks, with or without concomitant treatment with anti-
CD4 (c) or anti-ICOSL (d) depleting antibodies.  (a) Representative flow cytometry plots 
and percentage of CD44hiCD62L- T effector memory (TEM) and (b) Tfh 
(CD4+CXCR5hiPD1hi) cells with respect to total CD4+ T cells (each symbol represents an 
individual mouse; horizontal bars denote mean ± s.e.m.). (c-d) Representative images of 
Masson trichrome staining and quantification of atherosclerotic plaque area in aortic 
roots (each symbol represents an individual mouse; horizontal bars denote mean ± 
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s.e.m.). Original magnification, x10. Scale bars, 500 µm. For (a-d) two-tailed unpaired 
Student t-test or 2 way Anova * p<0.05; **p<0.01 and ***p<0.001. 
 
Figure 3. High cholesterol diet activates a homeostatic and anti-inflammatory 
program in MZB cells. (a) Clustered heat map of 92 genes that were differentially 
expressed in splenic MZB cells subjected to RNA-seq analysis, comparing cells sorted 
from Ldlr-/- mice fed a chow or a high cholesterol diet for 8 weeks (see Methods). Each 
group contains samples from 5 independent mice. (b) qRT-PCR validation of selected 
genes that were differentially expressed in the RNA-seq analysis (each symbol represents 
an individual mouse and horizontal bars denote mean ± s.e.m.); these mice were different 
than the ones used for the RNA-seq analysis. (c) Significantly enriched (P<0.01; 
Fischer´s exact test) Ingenuity canonical pathways in the differentially-expressed genes.  
Bars represent log Benjamini-Honchberg adjusted P value. In brackets, the number of 
differentially expressed genes (RNAseq analysis) that belong to each signaling pathway. 
In bold, selected signaling pathways related to B cell function. (d) Schematic diagram of 
BCR and TLR signaling pathways and their overlap with critical regulatory genes that are 
differentially expressed in MZB cells from mice fed a chow or high cholesterol diet, 
based on the RNA-seq analysis. The color code represents fold-change expression values 
overlaid onto the pathways: blue indicates down-regulated and red indicates up-regulated 
genes. Diagram also indicates potential relevant activating ligands (OxLDL, CpG DNA) 
and cellular localization of each molecule or gene product.  
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Figure 4. ATF3 expression in MZB cells controls Tfh accumulation in response to 
high cholesterol diet and is required for the atheroprotective effect of MZB cells. 
Quantitative mRNA expression for Il6 (a) and Cd274 (b), and protein expression (mean 
fluorescence intensity, MFI) of PDL1 by flow cytometry (c), in sorted MZB cells (a,b) or 
total B cells (c)  from WT or Atf3-/- mice treated with or without LPS (10 µg/mL) for 3 h 
(each symbol represents an individual mouse; horizontal bars denote mean ± s.e.m.). (d) 
Representative images of PDL1 (yellow) and IgM (magenta) immnostaining in spleen 
sections from Ldlr-/- mice transplanted with mixed BM containing 80% 
Cd79aCre/+;Rbpjkflox/flox BM plus 20% WT BM (WT MZB) or Atf3-/- BM (Atf3-/- MZB).  
BM from Cd274-/- mice was used as a negative control for PDL1 staining. White color 
indicates detection of PDL1 expression on IgM+ MZB cells. Original magnification, x40. 
Scale bars, 10 µm. (e) Quantitation of the percentage of PDL1-positive cells relative to 
total IgM-positive cells in the WT MZB and Atf3-/- MZB groups, as assessed by 
immunostaining. Each symbol represents an individual mouse; horizontal bars denote 
mean ± s.e.m. 100 MZB cells/mouse from at least 5 different sections were analyzed. (f-
g) Percentages of splenic Tfh (f) and GC (g) cells in the No MZB (Ldlr-/- mice 
transplanted with BM containing 100% Cd79aCre/+;Rbpjkflox/flox), WT MZB and Atf3-/- 
MZB groups.. (h) Representative images of Masson trichrome staining and quantification 
of atherosclerotic plaque area in aortic roots (each symbol represents an individual 
mouse; horizontal bars denote mean ± s.e.m.). Original magnification, x10. Scale bars, 
500 µm. (i) Quantification of atherosclerotic plaque area in aortic arches from en face oil 
red O-stained aortas. For (a-i) two-tailed unpaired Student t-test * p<0.05; **p<0.01 and 
***p<0.001. 
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Figure 5. MZB cells limit Tfh motility and control the pro-atherogenic Tfh-GC 
response through upregulation of PDL1. (a, b) Cd274 and Icosl mRNA expression in 
MZB (a) and (FOB) (b) cells sorted from Ldlr-/- mice fed a chow or high fat diet for 8 
weeks (each symbol represents an individual mouse; horizontal bars denote mean ± 
s.e.m.). (c-e) Sorted Tfh cells were co-cultured with sorted MZB or FOB cells from NP18-
OVA and lipid A-immunized C57Bl6 mice fed a chow diet (see Methods). Tfh cell 
movement was visualized by time-lapse microscopy (see Methods) in presence or 
absence of anti-PDL1 in the co-culture. (c) Plots of x-y displacement (in µm) of 
individual cell traces, with the starting position realigned to the same origin. (d) 
Quantification of the T-cell centroid velocity (µm/min) and (e) contact time (s) between 
Tfh and MZB or FOB cells (each symbol represents one Tfh-B cell interaction and 
horizontal bars denote mean ± s.e.m.). (f-h) Percentages of Tfh cells (f) and GC B cells 
(g) in Ldlr-/- mice transplanted with mixed BM containing 80% Cd79aCre/+;Rbpjkflox/flox  
BM plus 20% WT BM (WT MZB) or Cd274-/- BM (Cd274-/-  MZB); the mice consumed 
a HCD for 8 weeks. (h) Representative images of Masson trichrome staining and 
quantification of atherosclerotic plaque area in aortic roots (each symbol represents an 
individual mouse; horizontal bars denote mean ± s.e.m.). Original magnification, x10. 
Scale bars, 500 µm. For (a-h) two-tailed unpaired Student t-test * p<0.05; **p<0.01 and 
***p<0.001. 
 
Figure 6. MZB cells control the Tfh program during atherosclerosis.  (a) Clustered 
heat map of 109 genes that were differentially expressed in splenic Tfh cells subjected to 
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RNA-seq analysis, comparing cells sorted from Ldlr-/- mice transplanted with 
Cd79aCre/+/Rbpjkflox/flox BM or with Cd79a+/+/Rbpjkflox/flox BM and fed a high cholesterol 
diet for 8 weeks (see Methods). Each group contains biological samples from 4 
independent mice. (b) qRT-PCR validation of selected genes that were differentially 
expressed in the RNA-seq analysis. Each symbol represents an individual mouse; 
horizontal bars denote mean ± s.e.m. These mice were different than the ones used for the 
RNA-seq analysis. (c) Significantly enriched (P<0.01; Fischer´s exact test) Ingenuity 
canonical pathways in the differentially-expressed genes. Bars represent log Benjamini-
Honchberg adjusted P value. In brackets, the number of differentially expressed genes 
(RNAseq analysis) that belong to each signaling pathway. In bold, selected signaling 
pathways related to T cell function. (d) Schematic diagram showing critical Tfh 
regulatory genes that are differentially expressed in the RNA-seq analysis. The color 
code represents the fold-change values overlaid onto the pathways: blue indicates down-
regulated and red indicates up-regulated genes. Diagram also depicts the cell membrane.  
 
MATERIALS AND METHODS 
Animals. All experiments were approved by the Home Office, UK and were performed 
under PPL 80/2426. All mice were on a C57Bl/6 background. Cd79aCre/+, Cxcr5-/- and 
Ldlr–/– mice were originally from Jackson lab. Rbpjkflox/flox mice were kindly provided by 
Tasuku Honjo18; and Cd274-/- and Atf3-/- mice have been described51,52. Cd79aCre/+ were 
crossed with Rbpjkflox/flox to generate Cd79aCre/+/Rbpjkflox/flox and Cd79a+/+/Rbpjkflox/flox 
littermate mice. To study the role of MZB cells in atherosclerosis, 6-8-week-old Ldlr–/– 
male mice were lethally irradiated and injected i.v. with bone marrow from 
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Cd79aCre/+/Rbpjkflox/flox or Cd79a+/+/Rbpjkflox/flox mice. Ldlr–/– mice were randomly 
assigned to different experimental groups based on their weight at the beginning of the 
experiment. For some experiments, mixed BM containing 80% Cd79aCre/+/Rbpjkflox/flox 
BM plus 20% WT BM (for rescue experiments), 20% Cd274-/- BM or 20% Atf3-/- BM 
was injected. After 4 weeks recovery, mice were started on HCD (21% fat, 0.15% 
cholesterol) for 8 weeks. For depletion of CD4+ T or Tfh cells, mice received i.p. 
injections of purified neutralizing anti-CD4 (clone YTS 191.1, BioXCell) specific 
antibody (100 µg/mouse, every 10 days) or anti-ICOSL antibody (clone HK5.3, BioXCell) 
or isotype control (BioXCell) (100 g/mouse weekly).   
 
Flow cytometry. Single cell suspensions of bone marrow, spleen, lymph node, blood and 
peritoneal lavage were stained with fluorophore-conjugated antibodies (Supplemental 
Table 1) and analyzed using LSRII Fortessa (BD) or FACSCantoII (BD) flow 
cytometers. Dead cells were excluded based on FSc and SSc. B cells were identified as 
B220+ IgM+ or CD19+ lymphocytes, MZB cells as CD23lo/negCD21hi, FOB cells as 
CD23hiCD21lo/neg, T1 cells as CD23-CD21- and T2-MZP as CD23hiCD21hi; T cells were 
identified as CD3+ and either CD4+ or CD8+, Th1 cells as T-bet+, Th2 cells as GATA3+, 
Th17 cells as RORγt+ and Tfh cells as CD4+ PD1hi CXCR5hi ICOS+. Number of Tfh cells 
gated on CD4+ CXCR5hi PD1 hi BCL6+ Foxp3⎯ revealed a high correlation (r2=0.99) with 
the number of Tfh cells gated on CD4+ CXCR5 hi PD1 hi cells (data not shown). Germinal 
centre (GC) B cells were identified as CD19+ GL7hi and CD95hi cells. Monocytes were 
identified as CD11b+ and Ly6Chi/lo cells, neutrophils as Ly6G+ cells and macrophages as 
F4/80+ cells. 
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Extent and composition of atherosclerotic lesions. The lesions in the root of the aorta 
beneath all three-valve leaflets were analyzed. To measure atherosclerotic plaque size, we 
stained paraffin-embeded sections with Masson Trichrome. To characterize 
atherosclerotic lesion composition, we stained sections for macrophages (Mac-3, 1:200, 
clone M3/84, Santa Cruz), T cells (polyclonal CD3, 1:100, Dako, A0452). We performed 
each staining on a single slide (3 sections for each staining) from the same level of the 
aortic root for all experimental and control mice. Computer-assisted analysis (Image-J) 
was used to determine lesion size. The areas of specific cell types in the aortic cross-
sections from the same experiment were quantified by the same blinded observer to 
minimize variations. All measurements were performed by manual selection of stained 
pixel thresholds and presented as percent positive (stained) area to the entire intimal area. 
CD4+ T cells were counted and the data are presented as the number of T cells per total 
number of cells (DAPI) in atherosclerotic plaques. Whole aortas were used in an en face 
preparation for oil red O staining to measure aortic lipid deposition (considered as a 
measure of lesion size). Quantification was performed with J-Microvision. 
 
Measurement of circulating antibodies. Specific antibody titers to given antigens in 
plasma were determined by chemiluminescent ELISA, as previously described53, 54.  
 
Measurement of serum lipid levels. Total cholesterol and HDL-C were measured using 
an enzymatic method in a Siemens Dimensions RxL analyzer according to the 
manufacturer’s instructions. 
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Purification of MZB, FOB and Tfh cells. Single spleen cell suspensions were prepared 
by dissociation through 70 µm filters using a syringe plunger. For MZB and FOB cell 
purification, B cell enriched populations were first separated by autoMACS® Pro 
Separator (Miltenyi Biotech) using a B cell purification kit (Miltenyi Biotech) according 
to manufacturer´s instructions. B cells were then stained for 15 min at 4ºC with anti-
CD23-PE and anti-CD21-FITC. After washing and staining with 7-AAD for cell 
viability, MZB (CD21hiCD23low) and FOB (CD23hiCD21low) cells were sorted using 
AriaIII Cell, Influx or FACSJazz sorters (BD). The purity of both cell populations was 
higher than 95%. For Tfh cell purification, T cell enriched cell suspensions were 
separated by autoMACS® Pro Separator using a T cell purification kit (Miltenyi Biotech) 
according to manufacturer´s instructions. T cells were then stained for 15 min at 4ºC with 
anti-CD4-PECy7 and anti-CXCR5-PE. After washing and staining for 7-AAD to 
determine cell viability, Tfh cells (CD4+CXCR5hi) were sorted (purity >95%). 
 
Purification of human blood B cells. Anonymized apheresis cones with 10 mL of total 
blood were obtained from the Cambridge Blood Donor Centre in Addenbrooke´s 
Hospital. No further ethics approvals were requested to use the anonymized blood 
samples. PBMCs were isolated after density gradient centrifugation using Lymphoprep 
(Stemcell Technologies). B cells were then purified using a Miltenyi Human B cell 
purification kit for autoMACS® Pro Separator (Miltenyi Biotech). Naïve B cells were 
defined as CD19pos CD27neg and IgMneg; and MZB like cells were defined as CD19pos 
CD27pos IgMpos IgDpos CD21pos and CD1cpos (all from Biolegend).  
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Human spleen B cells. Adult spleen samples were obtained from 4 organ donors (18, 19, 
32, and 58 years old) with the authorization of the Agence de la 
Biomédecine, France (research protocol N° PF07-009). Informed consent was obtained 
for all patients. Spleen mononuclear cells were prepared from mechanically disrupted 
spleen samples after density gradient centrifugation on Ficoll-Paque PLUS (GE 
Healthcare). Staining was performed by incubating human splenocytes with the following 
antibodies: APC anti-CD27, APC-H7 
anti-CD19, PE-Cy7 anti-CD274 (all from BD Biosciences) and FITC 
anti-IgD (Invitrogen). Dead cells were excluded using Sytox Blue staining 
(Life technologies). Flow cytometric data acquisition was done with a 
FACSCantoII instrument, and the data were analyzed with Diva (BD Biosciences) 
software. 
 
BCR stimulation. Purified mouse B cells or sorted MZB and FOB cells were stimulated 
for 30 min, 3 hours or 6 hours with the F(ab)2 fragment of anti-IgM (eBioscience) (10 
ug/mL). Purified human B cells were cultured for 18 hours in pre-coated human anti-IgM 
(eBioscience) plates with soluble anti-CD40 (eBioscience). Ibrutinib, a phospho-Bruton´s 
tyrosine kinase (pBTK) inhibitor (Sellekchem) was used at 5 µM in DMSO. Control 
‘untreated’ cells were incubated with the same final concentration of DMSO. 
 
Tfh cell motility assay. C57Bl/6 mice were injected i.v. with OT-II CD4+ T cells from 
OT-II mice (Charles River). The following day, the mice were injected i.p. with NP18-
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OVA (Biosearch) and lipid A (Sigma-Aldrich). Mice were killed 8 days after injection 
and Tfh, MZB and FOB cells were sorted. For HCD MZB cells, MZB were sorted from 
mice that had been on an HCD diet for 8 weeks. CFSE-labeled MZB or FOB cells (4 x 
104) were co-cultured with Tfh cells (2 x 105) in rmICAM-1-Fc Chimera coated 
chambered coverglass (LAB-TEK®, NUNC). First, MZB or FOB cells were cultured for 
10 min with or without anti-PDL1 blocking antibody, and then the Tfh cells were added 
for another 10 min before starting imaging. Images were acquired using a Zeiss LSM710 
confocal microscope (20X lens) every 10 seconds for 20 minutes. To track cell motility, 
we used Volocity software (Improvision). T-cell/MZB-FOB interactions were then 
monitored by ImageJ Version 1.49 software. 
 
RNA sequencing. RNA was isolated from sorted MZB or Tfh cells using the mirVAna 
isolation kit (Ambion). The quality of the RNA extracted was checked using a 
Bioanalyser RNA Pico kit (Agilent) with RIN values > 7. RNA (2.5 ng) was whole 
transcriptome-amplified using the Ovation RNA-seq System V2 (NuGEN). To prepare 
the RNA-seq library, the amplified cDNA (2µg per sample) was fragmented to 200 bp 
using a Bioruptor Sonicator (Diagenode), and barcode ligation and end repair were 
performed using the Ovation Rapid DR Library System (NuGEN). The barcoded libraries 
were combined and loaded onto an Illumina HiSeq 2500 system for single end 50 bp 
sequencing at the Genomics Core Facility, Cambridge Institute, CRUK.  The sequencing 
yielded 213 million reads and the reads were aligned onto the mouse GRCm38 genome 
using Tophat 2.0.1155; the average mapping rate was 93.5%. Gene abundance and 
differential expression were determined with Cufflinks 2.2.156 and expressed in 
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fragments per kilobase per million of mapped reads (FPKM). Genes with a linear fold 
change of > 1.5 fold in FPKM and a Benjamini Hochberg False Discovery Rate < 10% 
were considered to be differentially expressed. 
 
Quantitative real time polymerase chain reaction. For gene expression analysis, RNA 
from sorted MZB, FOB and Tfh cells was isolated using an RNAeasy mini kit (Qiagen). 
RT-PCR was performed using a QuantiTect Reverse transcription kit (Qiagen) or a 
Quantitect Whole transcriptome kit depending on the yield of mRNA. qRT-PCR was 
performed with SYBR-green primers. Primers sequences are listed in Table 2S. 
 
Statistical analysis. Values are expressed as means ± s.e.m. Based on pilot experiments, 
we found that MZB deficiency increases lesion size by 2-fold. Use of the equation for 
Student's t test for the difference of 2 means gives n=6 for detection of a 50% increase in 
lesion size with α=0.05 and 90% power. Where data sets passed normality tests, 
differences between values were examined using the parametric two-tailed unpaired 
Student t-test or two-way ANOVA; other data sets were examined using the non-
parametric Mann Whitney U test, and were considered significant at P<0.05. 
Hypergeometric enrichment analysis of canonical pathways within the differentially 
regulated gene set was carried out using Ingenuity Pathway Analysis (Qiagen, Redwood 
City, CA, USA).  
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Editorial summary  
Marginal zone B cells in the spleen suppress atherosclerosis in mice by dampening the 
proatherogenic T follicular helper response, via interaction of PDL1 on marginal zone B 
cells with PD1 on T follicular helper cells.   
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Table S1. Flow Cytometry antibodies 
Target Clone Company 
B220 RA3-6B2 eBioscience 
IgM II-41 eBio 
MHC-II M5/114.15.2 Biolegend 
CD23 B3/B4 eBioscience 
CD21 eBio4E3 eBioscience 
CD69 H1.2F3 Biolegend 
CD44 1M7 Biolegend 
CD4 RM4-5 Biolegend 
CD3 145-2C11 Biolegend 
CD62L MEL-14 Biolegend 
CD95 Jo2 BD 
GL7 GL7 eBioscience 
B220 RA3-6B2 eBioscience 
CD19 1D3 BD 
CD138 281-2 Biolegend 
CD4 RM4-5 Biolegend 
CXCR5 L138D7 Biolegend 
ICOS C398.4A eBioscience 
PD1 
CD274 
RMP1-30 
MIH5 
Biolegend 
eBioscience 
pBtk M4G3LN eBioscience 
pSyk Moch1 ct eBioscience 
 
  
Table S2: Primers used for qRT-PCR 
 Sense 
 
Antisense 
A20  
 
TGGTTCCAATTTTGCTCCTT CGTTGATCAGGTGAGTCGTG 
Abcg1 
 
GGAAGATGTAGGACGGTTGG GAGCACAGGATGGCATTCTAT 
Fosb  
 
ATGTCTCCACTCTCAATG GTCACACTTACTTACAGAAG 
Atf3  
 
GCGAAGACTGGAGCAAAAT TGGATGGCGAATCTCAGCTC 
IL10  
 
ATGGCCCAGAAATCAAGGA CACAGGGGAGAAATCGATGA 
Junb  
 
GAACAGCCTTTCTATCAC TTTCAGGAGTTTGTAGTC 
Klf4  TTATTGTGTCGGAGGAAGAG TCACCAAGCACCATCATT 
 
Nur77  
 
CCCACTATTTGTCTTATCC CATCTCAACCTCTTCCTT 
Ccr7  
 
CTGAATGAACCTGCTTCT CTTGCTAAGTGTGGAGATAA 
Ebi2  
 
TGCTGCGATTCTCTGTAAT CTTAGGAACTTAGGAAGACCAT 
Cd274  
 
CTTCCTTCCTTCCTTCCT GCATAGTGAGCAACCATT 
Icosl  
 
AGGAATGAGGAGTGAGAAC ATTGAATACATCGGTGTGAAG 
IL6  
 
CCAGAGATACAAAGAAATGAT ACTCCAGAAGACCAGAGGAAA 
36B4  
 
TCTCCAGTGGCTCCATTGA CTCGCTGGCTCCCACCTT 
Il21 AAGCAATGATGGACAGAGA 
 
GTCAAGAAGTCAACAGTTACA 
Icos ATATGAGTTAGTTGGAAGGATT 
 
TAGGCATACAGACAGGAA 
S1pr1 TACACAGGCAAGTTGAAC 
 
AGCAGATGAGAATGAACAC 
Ascl2 TGACATCTTCCATCTTCC 
 
GAGTCCTACAACAGTTCA 
cMaf TTCTGAGTTCTTCTGATTG TTGATGTAGGCTTGATTG 
 
 
 
